胆汁酸治疗成人代谢功能障碍相关脂肪变性肝病

IF 8.8 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Cochrane Database of Systematic Reviews Pub Date : 2025-09-02 DOI:10.1002/14651858.CD014850

Rehab E Ashmawy, Oleg Blyuss, Dimitrinka Nikolova, Chavdar S Pavlov, Christian Gluud, Paola J Andrenacci

{"title":"胆汁酸治疗成人代谢功能障碍相关脂肪变性肝病","authors":"Rehab E Ashmawy, Oleg Blyuss, Dimitrinka Nikolova, Chavdar S Pavlov, Christian Gluud, Paola J Andrenacci","doi":"10.1002/14651858.CD014850","DOIUrl":null,"url":null,"abstract":"Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).","PeriodicalId":10473,"journal":{"name":"Cochrane Database of Systematic Reviews","volume":"9 ","pages":"CD014850"},"PeriodicalIF":8.8000,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403225/pdf/","citationCount":"0","resultStr":"{\"title\":\"Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.\",\"authors\":\"Rehab E Ashmawy, Oleg Blyuss, Dimitrinka Nikolova, Chavdar S Pavlov, Christian Gluud, Paola J Andrenacci\",\"doi\":\"10.1002/14651858.CD014850\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).\",\"PeriodicalId\":10473,\"journal\":{\"name\":\"Cochrane Database of Systematic Reviews\",\"volume\":\"9 \",\"pages\":\"CD014850\"},\"PeriodicalIF\":8.8000,\"publicationDate\":\"2025-09-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12403225/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cochrane Database of Systematic Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/14651858.CD014850\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cochrane Database of Systematic Reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/14651858.CD014850","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

目的：这是Cochrane综述（干预）的一个方案。目的如下：评估在诊断为代谢功能障碍相关脂肪变性肝病（MASLD）的成人患者中，口服胆汁酸为基础的治疗与不干预或安慰剂，或与不同剂量或方案的胆汁酸为基础的治疗相比的益处和危害。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Cochrane Database of Systematic Reviews 医学-医学：内科

CiteScore

10.60

自引率

2.40%

发文量

173

审稿时长

1-2 weeks

期刊介绍： The Cochrane Database of Systematic Reviews (CDSR) stands as the premier database for systematic reviews in healthcare. It comprises Cochrane Reviews, along with protocols for these reviews, editorials, and supplements. Owned and operated by Cochrane, a worldwide independent network of healthcare stakeholders, the CDSR (ISSN 1469-493X) encompasses a broad spectrum of health-related topics, including health services.